Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Financings Of The Fortnight Applies Its Own Lens To Early-Stage Investments

This article was originally published in The Pink Sheet Daily

Executive Summary

Plus news on recent financings by Neurocrine Biosciences, Prosensa, RaNA Therapeutics and Trius Therapeutics.

You may also be interested in...



Promethera's Cell Therapy Attracts Corporate VCs To Largest European Biopharma Funding Round This Year

Belgium's Promethera raises $31.4 million to start clinical trials of its cell therapy for orphan liver diseases in a Series B funding

Verastem Joins The Public Markets With A Strong IPO

Verastem IPO’d at $10 per share on Jan. 26, despite having only preclinical assets in its pipeline. Strong interest from large companies for cancer stem cell therapies helped contribute to the price.

Austerity Holds Back VC Investing in European Biotech Companies in 2011

Funding for private biotech companies in Europe declines 17% during 2011, while funding for public biotech companies falls 50%, although 2012 starts strongly.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

PS073311

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel